EHA-SWG Scientific Meeting on Integrated Diagnostics and Implementation Science in Hematological Malignancies

Abstract / case submission guidelines

Introduction

The abstract / case submission guidelines of the EHA-SWG Scientific Meeting on Integrated Diagnostics and Implementation Science in Hematological Malignancies are intended to provide clear instructions before submitting an abstract / case. **You are kindly requested to carefully read the guidelines stated below.**

The EHA and the Scientific Program Committee (SPC) of the meeting maintain the right to reject any abstract and clinical case submission that does not meet the requirements below.

Table of Contents

Key Dates 1

Abstract and clinical case submission 2

1. Terms and conditions 2
2. Applicable law and jurisdiction 2
3. Submission guidelines 3
4. Topics 3
5. Submission specifications 3
6. Review, selection and publication 4

Key Dates

Date	Item
October 15, 2026	Abstract / case submission open
January 15, 2027 (23:59 CET)	Abstract / case submission deadline
February 10, 2027	Notification to abstract submitters
February 28, 2027	Abstract / case withdrawal deadline

Abstract and clinical case submission

1. Terms and conditions

1) The Scientific Program Committee (SPC) encourages the submission of original scientific material unpublished at the time of the abstract/clinical submission deadline:
   I. Abstracts submitted to regional or national hematology meetings can be submitted to the meeting for inclusion in the program;
   II. Abstracts submitted to large international meetings which are organized in the same period as the EHA Scientific Meeting (March - May 2027) are allowed to be submitted to the meeting.;
   III. Abstracts/clinical cases submitted to other large international meetings may also be submitted providing a clear indication about significant novel or updated information included in the appropriate abstract submission field.
2) Authors of submitted abstracts shall be the sole and exclusive owner of the abstract and all associated intellectual property rights. By submitting the abstract to EHA, the author grants EHA the right to use and (commercial) reprint the abstract in relation to the Scientific Meeting. Authors of submitted abstracts understand and agree that EHA will not pay compensation for this license.
3) Authors of submitted abstracts guarantee that the abstract (and all associated intellectual property rights) is free of any third-party rights to the fullest extent permitted by law, including but not limited to, inventor's rights of remuneration and any other ancillary rights.
4) By submitting an abstract, the submitting author confirms that they have approval from all the co-authors to submit and use the data in the abstract.
5) Submitted abstracts are considered embargoed from the time of submission. The embargo is lifted at the start of the meeting.
6) Please do not submit the same study in multiple abstracts/clinical cases. Abstracts/clinical cases that appear as more than one version of a single study will be rejected.
7) Similarly, abstracts/clinical cases or (close) copies, may not be submitted under more than 1 (one) topic.

2. Applicable law and jurisdiction

The above Terms and conditions are governed by the laws of the Netherlands. Any dispute related to these terms and conditions and the use or publication of the abstract shall be exclusively submitted to the district court in the Hague, The Netherlands.

3. Submission guidelines

The submitted abstracts / clinical cases should fully adhere to the guidelines below.

1) Abstracts / clinical cases should be submitted in clear (American) English to allow the reviewers to focus on the scientific content of the abstract/clinical case. Non-English-speaking authors are encouraged to have their abstract/clinical case checked for grammar and spelling.
2) The SPC assumes all presenting authors have proficiency in English, thus are able to present and respond to questions.
3) In clinical studies, please state whether informed consent was obtained.
4) The title and text may not contain trade names.
5) If off label use of drugs was involved, please state this clearly.
6) Withdrawal policy: If authors wish to withdraw their abstracts/clinical cases from presentation or publication, they are requested to confirm with the EHA Executive Office via the confirmation form (provided in the notification letter) before **February 28, 2027 (23:59 CET)**. Consequently, the abstract/clinical case will not be presented nor published.

4. Topics

Abstract submissions should describe practical implementation experiences for use of integrated, innovative diagnostics in clinical settings (patients in trials or routine practice). Submissions should go beyond describing the problem: presenters are encouraged to share solutions they are testing or have tested locally or within networks (regional, national, or European).

Case studies may, but do not necessarily need to, address implementation challenges. Submissions from all participant and stakeholder groups are welcome — clinicians, laboratory professionals, bioinformaticians, regulators, industry partners, patient representatives, and health technology assessors.

Some case studies will be selected for oral presentation during a related scientific session (10 minutes presentation, followed by 10 minutes discussion).

You can submit under one of the following topics:

1. Availability of diagnostic tools (NGS, morphology, flow cytometry
2. Integrated diagnostics and multidisciplinary tumour board participation

3. Artificial intelligence: implementation and integration
4. Pragmatic, comprehensible consent for genetics and biobanking
5. Rare diseases
6. Mono. vs. oligo. vs. multicentric clinical studies
7. Industry and laboratory academics working together with real-world evidence (RWE)
8. Access and reimbursement
9. External Quality Assessment for in-house IVDs
10. Regulatory case studies (e.g., in-house NGS panels, CE-marked assay modifications)
11. Biomarker validation and clinical decision-making
12. Diagnostic inequalities and access across diverse healthcare settings

5. Submission specifications

1) Title count: max. 300 characters incl. space.
2) Character limit: 3500 characters (incl. spaces & punctuation and headers in the template).
3) Please use the following subheadings: Background / Aims / Methods / Results / Summary - Conclusion
4) Images have to be submitted as JPEG, tif, or gif files:
    I. Due to limited space, only a simple graph/image can be submitted;
    II. Images and graphs should reproduce well in black and white;
    III. Image file should not exceed 500KB.
5) Authors: There is no limit to the number of authors.
6) References are obligatory when submitting an abstract / clinical case.

6. Review, selection and publication

1) All submitted abstracts/clinical cases will be reviewed by the Scientific Program Committee of the EHA-SWG Scientific Meeting.
2) Abstracts/clinical cases may be selected for
    - oral presentation
    - poster presentation
    - rejection
3) Only the submitting author will receive a notification letter of acceptance for oral presentation, poster, or a notice of rejection, by email by **February 10, 2027**.
4) Authors of abstracts selected for an oral presentation or poster presentation will be informed about the date of the session, and presentation guidelines will be provided.
5) Oral and poster presenters will need to register themselves in order to present their abstracts in the Scientific Meeting.